Robert Detweiler, DO
Family Medicine · Lansdale, PANPI 1790751246
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,956 of the $2,720 with a category attached, or 71.9%. 29 manufacturers reported payments, led by Eli Lilly at 39.2% of the total. Reporting peaked in 2019 at $1,837 and has fallen 98.3% since, to $31 in 2025.
Across 109 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1K
- AstraZeneca$286
- AbbVie$196
- Biohaven Pharmaceutical Holding Company Ltd.$113
- Sunovion Pharmaceuticals Inc.$109
- Sanofi-aventis U.S. LLC$106
- plus $846 from 23 others
Across 49 payments — averaging $14,103 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$642K
- Novo Nordisk AS$29K
- Sanofi US Services Inc.$14K
- Novartis$5K
- Merck$1K
What the payments were for
- Travel & lodging$76428%
- Food & beverage$1,95672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 24 | $1,065 |
| AstraZeneca | 7 | $286 |
| AbbVie(2 entities) | 9 | $196 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $113 |
| Sunovion Pharmaceuticals Inc. | 8 | $109 |
| Sanofi-aventis U.S. LLC | 6 | $106 |
| Johnson & Johnson(2 entities) | 6 | $91 |
| Amgen | 6 | $79 |
| Alk-abello, Inc | 4 | $74 |
| Merck | 5 | $61 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Pfizer | 4 | $54 |
| Novartis | 3 | $44 |
| Amarin Pharma, Inc. | 3 | $44 |
| GSK | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Exact Sciences | 2 | $38 |
| Biofire Diagnostics, LLC | 1 | $35 |
| Novo Nordisk | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $13 |
| Upsher-smith Laboratories LLC | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$220
- NURTEC ODT$113
How this compares
$2,720 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $70,584 |
| EliquisApixaban | 50 | $60,237 |
| JardianceEmpagliflozin | 48 | $53,358 |
| JanuviaSitagliptin Phosphate | 29 | $44,011 |
| FarxigaDapagliflozin Propanediol | 31 | $30,238 |
| XareltoRivaroxaban | 22 | $28,425 |
| TrulicityDulaglutide | 18 | $26,440 |
| TradjentaLinagliptin | 18 | $23,650 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,369 |
| MounjaroTirzepatide | 12 | $12,703 |
| MyrbetriqMirabegron | 17 | $10,870 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $10,742 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $9,397 |
| OxycontinOxycodone Hcl | 18 | $8,199 |
| Atorvastatin Calcium | 496 | $6,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $24 | $70,58445 claims |
| PfizerEliquis | $54 | $60,23750 claims |
| MerckJanuvia | $61 | $44,01129 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $18 | $39,14430 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $40 | $33,39851 claims |
| AstraZenecaFarxiga | $286 | $30,23831 claims |
| Johnson & JohnsonXarelto | $91 | $28,42522 claims |
| AbbVieSynthroid | $196 | $3,31662 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Lansdale
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.